Opendata, web and dolomites

SilkFUSION SIGNED

Genetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bio-inks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SilkFUSION project word cloud

Explore the words cloud of the SilkFUSION project. It provides you a very rough idea of what is the project "SilkFUSION" about.

acute    environment    trauma    proven    55    specialized    clinical    extremely    successful    physical    safety    bio    massive    immunologically    megakaryocytes    release    hpscs    thrombocytopenic    live    proteins    engineer    transfusions    regarding    pathogenetic    clinicians    ing    nanotechnologies    ineffective    genetically    wounded    fviia    pluripotent    marrow    ex    affordable    platelet    innovative    efficacy    alloimmunised    groundbreaking    medical    fibroin    plts    surgery    recombinant    molecules    stem    correct    primary    screening    supply    modified    humans    instruments    plt    predicting    bone    containing    hypothesis    conflict    inherited    biomaterial    ink    thrombogenic    3d    platforms    reducing    create    biochemical    demand    technological    silk    reproducible    supercharged    disorders    generating    therapeutic    patients    therapies    transfusion    drugs    mks    human    mechanisms    kits    platelets    model    prove    cells    silkfusion    gain    chip    suited    engineering    strategies    vitro    dimensional    vivo    haemorrhage    precision    matched    fold    platform    printing    blood    drug    functional    vision    optimized    zones   

Project "SilkFUSION" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI PAVIA 

Organization address
address: STRADA NUOVA 65
city: PAVIA
postcode: 27100
website: www.unipv.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://silkfusion.eu/
 Total cost 2˙998˙500 €
 EC max contribution 2˙998˙500 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-1-2016-2017
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI PAVIA IT (PAVIA) coordinator 738˙327.00
2    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) participant 688˙327.00
3    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 688˙327.00
4    CELLINK AB SE (GOTEBORG) participant 344˙163.00
5    INTEGRATED SYSTEMS ENGINEERING SRL IT (BRUGHERIO) participant 319˙580.00
6    KNOWLEDGE INNOVATION MARKET S.L. ES (BARCELONA) participant 219˙773.00

Map

 Project objective

'The demand for human platelets (plts) for medical research and clinical applications is massive. The primary goal of SilkFUSION is to engineer groundbreaking 3D nanotechnologies for large-scale production of blood plts for human transfusion from human pluripotent stem cells (hPSCs). Our hypothesis is that plt production ex-vivo can be optimized by providing megakaryocytes (Mks) with the correct physical and biochemical environment.

To prove this, we will develop a unique technological platform by engineering non-thrombogenic silk-fibroin biomaterial with proteins, that were proven to promote a 55-fold gain in plt production, to create a three-dimensional ex-vivo bone marrow model that will enhance plt release from Mks derived from hPSCs. Our platform will include (i) novel applications to study pathogenetic mechanisms in patients with inherited platelet production disorders using genetically modified hPSCs; (ii) screening technology for predicting therapeutic efficacy of drugs for thrombocytopenic patients. The development of this technology will exploit an extremely innovative approach using silk-fibroin as a bio-ink for 3D printing a 'live chip' containing viable Mks for reproducible drug testing.

Our long-term vision is to foster the production of plts in-vitro for clinical transfusions in humans at a scale and cost that will address current supply challenges regarding (i) immunologically matched products to alloimmunised patients; (ii) “supercharged” platelets with recombinant FVIIa generating plts specifically suited for patients with acute haemorrhage resulting from trauma, surgery and wounded in conflict zones. The successful development and distribution of the SilkFUSION platforms will also offer researchers and clinicians specialized precision instruments and bio-ink kits for determining the safety and efficacy of drugs, reducing costs of ineffective therapies while promoting affordable functional strategies for the development of novel molecules.'

 Deliverables

List of deliverables.
Public Project website Websites, patent fillings, videos etc. 2020-03-18 18:53:14
Targeted stakeholders identified and informed about the project_12 Documents, reports 2020-03-18 18:53:14
Workshops_12 Documents, reports 2020-03-18 18:53:14

Take a look to the deliverables list in detail:  detailed list of SilkFUSION deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Lorenzo Tozzi, Pierre-Alexandre Laurent, Christian A. Di Buduo, Xuan Mu, Angelo Massaro, Ross Bretherton, Whitney Stoppel, David L. Kaplan, Alessandra Balduini
Multi-channel silk sponge mimicking bone marrow vascular niche for platelet production
published pages: 122-133, ISSN: 0142-9612, DOI: 10.1016/j.biomaterials.2018.06.018
Biomaterials 178 2020-03-18
2018 Jennifer H. Shepherd, Daniel Howard, Amie K. Waller, Holly Rebecca Foster, Annett Mueller, Thomas Moreau, Amanda L. Evans, Meera Arumugam, Guénaëlle Bouët Chalon, Eleonora Vriend, Natalia Davidenko, Cedric Ghevaert, Serena M. Best, Ruth E. Cameron
Structurally graduated collagen scaffolds applied to the ex vivo generation of platelets from human pluripotent stem cell-derived megakaryocytes: Enhancing production and purity
published pages: 135-144, ISSN: 0142-9612, DOI: 10.1016/j.biomaterials.2018.08.019
Biomaterials 182 2020-03-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SILKFUSION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SILKFUSION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

FLIX (2020)

FLow chemistry for Isotopic eXchange

Read More  

EDRA (2019)

Hardware-Assisted Decoupled Access Execution on the Digital Market: The EDRA Framework

Read More  

ph-coding (2019)

Predictive Haptic COding Devices In Next Generation interfaces

Read More